Sangamo BioSciences | SGMO - Interest Expense On Debt


Sangamo BioSciences reported 97.56M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.





Interest Expense On Debt Change Date
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
Amgen USD 653M 94.99B Sep/2026
Bayer EUR 675M 87M Dec/2025
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Cipla INR 167.4M 2.9M Sep/2026
Compugen USD 1.84M 485K Jun/2026
CSL USD 215M 111M Dec/2025
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Grifols EUR 156.07M 31.46M Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Merck USD 525M 46M Jun/2026
Novartis USD 468M 6M Sep/2026
Omeros USD 4.05M 5.16M Sep/2024
Pfizer USD 662M 5M Sep/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 222M 65M Sep/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Tectonic Therapeutic USD 237.03M 9.54M Jun/2026
Ultragenyx Pharmaceutical USD 20M 2M Sep/2026
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026